Meeting
2019 ASCO Annual Meeting
Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors
Kedar Kirtane
Moffitt Cancer Center, Tampa, FL
Kedar Kirtane , Jameel Muzaffar , Robbert Slebos , Christine H. Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6044)
DOI
10.1200/JCO.2019.37.15_suppl.6044
Abstract #
6044
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.
First Author: Bailey Fabiny Garb
Poster
2021 ASCO Annual Meeting
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Deborah J.L. Wong
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.
First Author: Ralph Zinner
Poster
2019 ASCO Annual Meeting
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.
First Author: Martin David Forster